Committee for Stroke Guideline, the Japan Stroke Society (2021), The Japan Stroke Society (2023) guideline 2021 for the treatment of stroke [revised version 2023]. Kuroda S (ed). Kyowa Kikaku Ltd. [In Japanese]

Shah J, Liu S, Yu W (2022) Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines. Stroke Vasc Neurol 7:406–414. https://doi.org/10.1136/svn-2021-001166

Article  PubMed  PubMed Central  Google Scholar 

Han Y, Lv HH, Liu X, Dong Q, Yang XL, Li SX, Wu S, Jiang JM, Luo Z, Zhu DS, Zhang Y, Zheng Y, Guan YT, Xu JF (2015) Influence of genetic polymorphisms on clopidogrel response and clinical outcomes in patients with acute ischemic stroke CYP2C19 genotype on clopidogrel response. CNS Neurosci Ther 21:692–697. https://doi.org/10.1111/cns.12426

Article  CAS  PubMed  PubMed Central  Google Scholar 

Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T (2005) Influence of CYP2C19 Pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 20:153–167. https://doi.org/10.2133/dmpk.20.153

Article  CAS  PubMed  Google Scholar 

Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ (1999) Allelic, genotypic and phenotypic distributions of S-mephenytoin 4’-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 9:539–149

Article  CAS  PubMed  Google Scholar 

Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, Pan Y, Liu L, Wang D, Wang C, Meng X, Xu J, Wang Y, CHANCE investigators (2016) Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA 316:70–78. https://doi.org/10.1001/jama.2016.8662

Article  CAS  PubMed  Google Scholar 

Pharmaceuticals and Medical Development Agency (2024) Efient® Tablets. [In Japanese]. https://www.info.pmda.go.jp/go/pdf/430574_3399009F1020_1_21. Accessed 7 June

Ogawa A, Toyoda K, Kitagawa K, Kitazono T, Nagao T, Yamagami H, Uchiyama S, Tanahashi N, Matsumoto M, Minematsu M, Nagata K, Nishikawa I, Nanto S, Abe K, Ikeda Y, PRASTRO-I Study Group (2019) Comparison of Prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I). Lancet Neurol 18:238–247. https://doi.org/10.1016/S1474-4422(18)30449-6. Erratum in: Lancet Neurol 2020 19:e8. https://doi.org/10.1016/S1474-4422(20)30268-4

Article  CAS  PubMed  Google Scholar 

Kitagawa K, Toyoda K, Kitazono T, Nishikawa M, Nanto S, Ikeda Y, Abe K, Ogawa A (2020) Safety and efficacy of Prasugrel in elderly/low body weight Japanese patients with ischemic stroke: randomized PRASTRO-II. Cerebrovasc Dis 49:152–159. https://doi.org/10.1159/000506825

Article  CAS  PubMed  Google Scholar 

Kitazono T, Kamouchi M, Matsumaru Y, Nakamura M, Umemura K, Matsuo H, Koyama N, Tsutsumi J, Kimura K (2023) Efficacy and safety of Prasugrel vs clopidogrel in thrombotic stroke patients with risk factors for ischemic stroke recurrence: a double-blind, phase III study (PRASTRO-III). J Atheroscler Thromb 30:222–236. https://doi.org/10.5551/jat.63473

Article  CAS  PubMed  Google Scholar 

Kitazono T, Kamouchi M, Matsumaru Y, Shirai T, Takita A, Kuroda T, Kimura K (2023) Comparison of Prasugrel and clopidogrel in thrombotic stroke patients with risk factors for ischemic stroke recurrence: an integrated analysis of PRASTRO-I, PRASTRO-II, and PRASTRO-III. Cerebrovasc Dis 52:720–729. https://doi.org/10.1159/000529149

Article  CAS  PubMed  Google Scholar 

Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD, ADAPT-DES Investigators (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382:614–623. https://doi.org/10.1016/S0140-6736(13)61170-8. Erratum in: Lancet 2014 383:1128

Article  PubMed  Google Scholar 

Nakamura M, Kadota K, Takahashi A, Kanda J, Anzai H, Ishii Y, Shibata Y, Yasaka Y, Takamisawa I, Yamaguchi J, Takeda Y, Harada A, Motohashi T, Iijima R, Uemura S, Murakami Y, PENDULUM Registry Investigators* (2020) Relationship between platelet reactivity and ischemic and bleeding events after percutaneous coronary intervention in East Asian patients: 1-year results of the PENDULUM registry. J Am Heart Assoc 9(e015439). Erratum in: J Am Heart Assoc 2020 9:e014557. https://doi.org/10.1161/JAHA.119.015439

Angiolillo DJ, Capodanno D, Danchin N, Simon T, Bergmeijer TO, Ten Berg JM, Sibbing D, Price MJ (2020) Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score. JACC Cardiovasc Interv 13:606–617. https://doi.org/10.1016/j.jcin.2020.01.226

Article  PubMed  Google Scholar 

Tanaka T, Yamagami H, Ihara M, Miyata T, Miyata S, Hamasaki T, Amano S, Fukuma K, Yamamoto H, Nakagawara J, Furui E, Uchiyama S, Hyun B, Yamamoto Y, Manabe Y, Ito Y, Fukunaga R, Abumiya T, Yasaka M, Kitagawa K, Toyoda K, Nagatsuka K (2019) Association of CYP2C19 polymorphisms with clopidogrel reactivity and clinical outcomes in chronic ischemic stroke. Circ J 83:1385–1393. https://doi.org/10.1253/circj.CJ-18-1386

Article  CAS  PubMed  Google Scholar 

Fukuma K, Yamagami H, Ihara M, Tanaka T, Miyata T, Miyata S, Miyata S, Kokame K, Nishimura K, Nakaoku Y, Yamamoto H, Hayakawa M, Kamiyama K, Enomoto Y, Itabashi R, Furui E, Manabe Y, Ezura M, Todo K, Hashikawa K, Uchiyama S, Toyoda K, Nagatsuka K (2023) P2Y12 reaction units and clinical outcomes in acute large artery atherosclerotic stroke: a multicenter prospective study. J Atheroscler Thromb 30:39–55. https://doi.org/10.5551/jat.63369

Article  CAS  PubMed  Google Scholar 

Adams HP Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke 24:35–41. https://doi.org/10.1161/01.str.24.1.35

Article  PubMed  Google Scholar 

Price MJ (2009) Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 119:2625–2632. https://doi.org/10.1161/CIRCULATIONAHA.107.696732

Article  PubMed  Google Scholar 

Nagao T, Toyoda K, Kitagawa K, Kitazono T, Yamagami H, Uchiyama S, Tanahashi N, Matsumoto M, Minematsu K, Nagata I, Nishikawa M, Nanto S, Abe K, Ikeda Y, Ogawa A (2018) A noninferiority confirmatory trial of Prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial - PRASTRO-I trial. Expert Opin Pharmacother 19:529–535. https://doi.org/10.1080/14656566.2018.1444029

Article  CAS  PubMed  Google Scholar 

Nakamura M, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Ikeda Y, Saito S (2015) Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: post-hoc analysis of the randomized PRASFIT-ACS study. Int J Cardiol 182:541–548. https://doi.org/10.1016/j.ijcard.2015.01.026

Article  PubMed  Google Scholar 

Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Ikeda Y, Nakamura M, Saito S, PRASFIT-Elective Investigators (2014) Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. Circ J 78:2926–2934. https://doi.org/10.1253/circj.cj-14-0266

Article  CAS  PubMed  Google Scholar 

Sawayama Y, Yamamoto T, Tomita Y, Asada K, Yagi N, Fukuyama M, Miyamoto A, Sakai H, Ozawa T, Isono T, Hira D, Terada T, Horie M, Nakagawa Y (2020) Comparison between clopidogrel and Prasugrel associated with CYP2C19 genotypes in patients receiving percutaneous coronary intervention in a Japanese population. Circ J 84:1575–1581. https://doi.org/10.1253/circj.CJ-20-0254

Article  CAS  PubMed  Google Scholar 

Kitano D, Takayama T, Fukamachi D, Migita S, Morikawa T, Tamaki T, Kojima K, Mineki T, Murata N, Akutsu N, Sudo M, Hiro T, Hirayama A, Okumura Y (2020) Impact of low-dose Prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: a randomized comparative study. Catheter Cardiovasc Interv 95:E8–16. https://doi.org/10.1002/ccd.28277

Article  PubMed  Google Scholar 

Ueno T, Koiwaya H, Sasaki KI, Katsuki Y, Katsuda Y, Murasato Y, Shimamatsu J, Umeji K, Otsuka Y, Kawasaki T, Shibata Y, Fukumoto Y (2017) Changes in P2Y12 reaction units after switching treatments from Prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting. Cardiovasc Interv Ther 32:341–350. https://doi.org/10.1007/s12928-016-0417-x

Article  CAS  PubMed  Google Scholar 

Kitazono T, Ikeda Y, Nishikawa M, Yoshiba S, Abe K, Ogawa A (2018) Influence of cytochrome P450 polymorphisms on the antiplatelet effects of Prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel. J Thromb Thrombolysis 46:488–495. https://doi.org/10.1007/s11239-018-1714-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamaguchi T, Shirai T, Yoshiba S, Abe K, Ikeda Y (2020) Pharmacodynamic assessment of Prasugrel and clopidogrel in patients with non-cardioembolic stroke: a multicenter, randomized, active-control clinical trial. J Thromb Thrombolysis 49:10–17. https://doi.org/10.1007/s11239-019-01926-6

Article  PubMed  Google Scholar 

Lim ST, Thijs V, Murphy SJX, Fernandez-Cadenas I, Montaner J, Offiah C, Marquardt L, Kelly PJ, Bath PM, Lim SY, Ford GA, Norrving B, Cox D, Prodan CI, Barber PA, Werring DJ, Perry R, Zgaga L, Dawson J, McCabe DJH (2020) Platelet function/reactivity testing and prediction of risk of recurrent vascular events and outcomes after TIA or ischaemic stroke: systematic review and meta-analysis. J Neurol 267:3021–3037. https://doi.org/10.1007/s00415-020-09932-y

Article  PubMed  Google Scholar